Dimerosesquiterpene and sesquiterpene lactones from Artemisia argyi inhibiting oncogenic PI3K/AKT signaling in melanoma cells

25 July 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

A library of more than 2’500 plant extracts were screened for their activity on oncogenic signaling in melanoma cells. The ethyl acetate extract from aerial parts of Artemisia argyi displayed pronounced inhibition of the PI3K/AKT pathway. Active compounds were tracked with the aid of HPLC-based activity profiling, and a total of 21 active compounds were isolated, including one novel dimerosequiterpenoid (1), one new disesquiterpenoid (2), three new guaianolides (3-5), 12 known sesquiterpenoids (6-17), as well as four known flavonoids (19-22). A new eudesmanolide derivative (13b) was isolated as an artifact formed by methanolysis. Compound 1 is the first adduct comprising a sesquiterpene lactone and a methyl jasmonate moiety. The absolute configurations of compounds 1 and 3-18 were established by comparison of experimental and calculated ECD spectra. The absolute configuration for 2 was determined by X-ray diffraction. Guaianolide 8 was the most potent sesquiterpene lactone, inhibiting the PI3K/AKT pathway with an IC50 of 8.9 ± 0.9 μM

Keywords

Natural Product
Sesquiterpene lactone
Melanoma
PI3/AKT pathway inhibitor
ECD

Supplementary materials

Title
Description
Actions
Title
Supporting information
Description
Tables with NMR spectroscopic data of all isolated compounds are provided. Figures of activity profiles of Artemisia argyi extracts, crystal data for compound 2, NMR spectra, as well as concentration response curves are provided
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.